What is melphalan flufenamide, and what is it used for?
Melphalan flufenamide (often shortened to melflufen) is an anticancer drug that was developed for hematologic cancers, particularly multiple myeloma. It was studied in settings where patients had already received prior therapies, including combinations with other anti-myeloma treatments. [1]
How does melphalan flufenamide work?
Melphalan flufenamide is designed as a “peptide-drug” that delivers the chemotherapy agent melphalan more selectively into cells. Once inside, it is broken down to release melphalan, which then damages DNA and kills cancer cells. [1]
What evidence supports it in multiple myeloma?
Melphalan flufenamide was evaluated in clinical trials in patients with relapsed or refractory multiple myeloma. Trial results and subsequent confirmatory studies shaped regulatory decisions and product availability over time. [1]
Why did melphalan flufenamide become controversial or restricted?
As more clinical data accumulated, regulators and clinicians faced questions about the balance of benefits versus risks compared with existing standards of care. This contributed to changes in its regulatory status and, in practice, reduced use in later periods. [1]
What is its current status—can patients still get it?
Melphalan flufenamide’s availability depends on country and regulatory actions. In many markets, it was eventually withdrawn or restricted after review of evidence and safety/benefit considerations. If you’re looking for whether it can be prescribed where you live, the answer is tied to your national regulator and current oncology formularies. [1]
Are there alternatives for relapsed/refractory multiple myeloma?
Common alternatives depend on prior treatments and patient factors, but multiple myeloma care now often includes drugs and regimens from several classes (for example, proteasome inhibitors, immunomodulatory drugs, and anti-CD38 therapies), plus newer agents. The best option depends on what the patient has already received and disease risk features. [1]
If a study or paper mentions melphalan flufenamide, how should readers interpret it?
Because melphalan flufenamide’s clinical adoption changed over time, studies may reflect different eras of myeloma therapy. When reading research, it matters whether trials compared it against current standards at the time, what patient subgroup was enrolled, and what the primary endpoints were (response, duration of response, progression-free survival, and overall survival). [1]
Sources
[1] https://en.wikipedia.org/wiki/Melphalan_flufenamide